Answer
Sep 26, 2024 - 01:57 PM
Do you have the same question? Follow this Question
Sep 26, 2024 - 01:57 PM
We’ve provided several answers to questions related to Ubrelvy (Ubrogepant) , see some other helpful Q&A related to this product.
Question: Who should not take Ubrelvy?
Answer: Ubrelvy should not be taken by people with severe liver problems or a history of allergic reactions to ubrogepant. Avoiding the drug in these cases prevents serious health complications.
Question: What is the active ingredient in Ubrelvy?
Answer: The active ingredient in Ubrelvy is ubrogepant. This ingredient is responsible for the drug's therapeutic effects in treating migraines by blocking the action of CGRP.
Question: What is the PubChem CID for Ubrelvy?
Answer: The PubChem CID for Ubrelvy is 68748835. This identifier helps researchers and healthcare professionals locate detailed chemical information about the drug.
Question: What is the bioavailability of Ubrelvy?
Answer: The bioavailability of Ubrelvy is 40% when taken orally. This means that 40% of the drug reaches the bloodstream when ingested, which is an important factor in determining the effective dosage for treating migraines.